Holen Sie sich die Stockscreener-App
13.02
1.15%
0.095
Schlusskurs vom Vortag:
$12.92
Offen:
$12.7
24-Stunden-Volumen:
159.88K
Relative Volume:
0.10
Marktkapitalisierung:
$1.67B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-45.86M
KGV:
-35.05
EPS:
-0.3713
Netto-Cashflow:
$-44.02M
1W Leistung:
+13.44%
1M Leistung:
+19.45%
6M Leistung:
+86.42%
1J Leistung:
+197.68%
1-Tages-Spanne:
$12.66
$13.23
1-Wochen-Bereich:
$11.30
$13.51
52-Wochen-Spanne:
$4.24
$14.39
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Firmenname
Trevi Therapeutics Inc
Sektor
Branche
Telefon
203-304-2499
Adresse
195 CHURCH STREET, NEW HAVEN, CT
Compare TRVI vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
12.99 | 1.66B | 0 | -45.86M | -44.02M | -0.3713 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.18 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.05 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
731.68 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.49 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
295.38 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-13 | Eingeleitet | Leerink Partners | Outperform |
| 2025-08-21 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-07-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-05-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-10 | Bestätigt | Needham | Buy |
| 2025-03-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | Bestätigt | H.C. Wainwright | Buy |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-30 | Eingeleitet | Raymond James | Outperform |
| 2024-06-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-04-12 | Eingeleitet | B. Riley Securities | Buy |
| 2022-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-06-03 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-06-03 | Eingeleitet | Needham | Buy |
| 2019-06-03 | Eingeleitet | SVB Leerink | Outperform |
| 2019-06-03 | Eingeleitet | Stifel | Buy |
Alle ansehen
Trevi Therapeutics Inc Aktie (TRVI) Neueste Nachrichten
Value Recap: Can Trevi Therapeutics Inc continue delivering strong returnsJuly 2025 Chart Watch & Advanced Technical Signal Analysis - baoquankhu1.vn
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Trevi Therapeutics, Inc. Senior Management to Present at 2026 Healthcare Conferences - Quiver Quantitative
Chronic cough treatment talks: Trevi execs head to Miami and Philly in March - Stock Titan
MAI Capital Management Cuts Stock Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Assessing Trevi Therapeutics (TRVI) Valuation After Strong Long Term Returns And A Rich Price To Book Ratio - Yahoo Finance
TRVI Should I Buy - Intellectia AI
TRVI PE Ratio & Valuation, Is TRVI Overvalued - Intellectia AI
Trevi Therapeutics, Inc. (TRVI) Stock Analysis: Promising 87% Potential Upside Captures Investor Attention - DirectorsTalk Interviews
TRVI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Does Trevi Therapeutics (TRVI) Have the Potential to Rally 102.07% as Wall Street Analysts Expect? - Finviz
[Form 4] Trevi Therapeutics, Inc. Insider Trading Activity - Stock Titan
Trevi Therapeutics (TRVI) officer receives 35,000-share stock option grant - Stock Titan
Executive at Trevi (NASDAQ: TRVI) granted 160,000 stock options - Stock Titan
Trevi Therapeutics (TRVI) CSO awarded stock options on 85,000 shares - Stock Titan
EV Market: Can Trevi Therapeutics Inc continue delivering strong returnsWeekly Trade Report & Risk Managed Investment Entry Signals - baoquankhu1.vn
Will Trevi Therapeutics Inc. outperform its industry peersJuly 2025 Volume & AI Driven Stock Price Forecasts - mfd.ru
Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Bitget
Trevi Therapeutics Executives to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference - Quiver Quantitative
Trevi Therapeutics, Inc. (TRVI) Stock Analysis: A Promising 99% Potential Upside In Biotech - DirectorsTalk Interviews
Can Trevi Therapeutics Inc. disrupt its industryDay Trade & Safe Investment Capital Preservation Plans - mfd.ru
Is Trevi Therapeutics Inc. stock resilient to inflationGold Moves & Fast Entry High Yield Stock Tips - mfd.ru
New Haven biotech Trevi Therapeutics builds billion-dollar valuation around lone late-stage cough drug - Hartford Business Journal
Fed Watch: Can Trevi Therapeutics Inc continue delivering strong returns2025 Market Trends & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
Analysts Conflicted on These Healthcare Names: Encompass Health (EHC), Hims & Hers Health (HIMS) and Trevi Therapeutics (TRVI) - The Globe and Mail
Aug Outlook: How does Trevi Therapeutics Inc compare to its peersQuarterly Earnings Summary & AI Driven Price Predictions - baoquankhu1.vn
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of "Buy" by Brokerages - MarketBeat
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of “Buy” by Brokerages - Defense World
Wall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's What You Should Know - MSN
Tejara Capital Ltd Trims Stock Position in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics Advances Toward Treatment for Debilitating Cough - AD HOC NEWS
Trevi Therapeutics, Inc. (TRVI) Stock Analysis: Strong Buy Ratings and Nearly 100% Upside Potential - DirectorsTalk Interviews
Will Trevi Therapeutics Inc. benefit from rate cutsJuly 2025 Review & Technical Confirmation Trade Alerts - mfd.ru
Can Trevi Therapeutics Inc. continue delivering strong returnsWeekly Profit Analysis & High Accuracy Trade Alerts - mfd.ru
ETF Watch: Is Nabors Industries Ltd showing insider buyingTrade Exit Summary & Growth Oriented Trading Recommendations - baoquankhu1.vn
Weekly Recap: Does Trevi Therapeutics Inc offer margin of safetyShort Setup & Verified High Yield Trade Plans - baoquankhu1.vn
Coulter Partners Recruits CFO for Trevi Therapeutics - Hunt Scanlon Media
Is Trevi Therapeutics Inc a momentum stockEarnings Performance Report & Detailed Earnings Play Strategies - baoquankhu1.vn
Trevi Therapeutics Advances Toward Key Regulatory Review Following Clinical Validation - AD HOC NEWS
Trevi Therapeutics (NASDAQ:TRVI) Shares Down 6.5%Here's Why - MarketBeat
Trevi Therapeutics (TRVI) Stock Price Prediction: Today, Tomorrow, Next Week - Traders Union
Trevi Therapeutics Reports Positive Results on Treatment for Chronic Cough; Shares Rise - marketscreener.com
Trevi Therapeutics (TRVI) Publishes Positive Phase 2b Trial Resu - GuruFocus
Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA) - PR Newswire
Aug Action: Is Trevi Therapeutics Inc a top pick in the sectorJuly 2025 PreEarnings & Low Risk High Win Rate Picks - baoquankhu1.vn
Is Trevi Therapeutics Inc. stock technically oversoldBear Alert & Accurate Buy Signal Alerts - bollywoodhelpline.com
Trevi Therapeutics, Inc. (TRVI) Stock Analysis: Exploring A Nearly 98% Upside Potential - DirectorsTalk Interviews
New trial links cough counts to how IPF patients feel on oral treatment - Stock Titan
Will Trevi Therapeutics Inc outperform tech stocksPortfolio Gains Summary & Daily Stock Trend Watchlist - baoquankhu1.vn
Trevi Therapeutics’ Earnings Call Highlights Promising Outlook - MSN
Coulter Partners successfully led a search assignment for Trevi Therapeutics, Inc. (Nasdaq: TRVI) and is pleased to announce the placement of David Hastings as Chief Financial Officer (CFO) - Hunt Scanlon Media
Finanzdaten der Trevi Therapeutics Inc-Aktie (TRVI)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):